The Annual Clinical Trials Roundup 2024 Edition: Promising Road to Recovery
White paper
Clinical
Last updated: Nov 7, 2025
Trialtrove curated 9,959 Phase I–III clinical trials investigating at least one drug with a disclosed 2023 start, returning growth of 9.4%, a remarkable recovery from the previous year’s decline.
Introduction
Welcome to the 2024 edition of Clinical Trials Roundup. Last year, we unveiled a landscape of increasing complexity, culminating in an unprecedented decline of clinical trial initiations. The biopharma industry weathered postpandemic adjustments, endured economic hardships and slowed growth in major markets, met regulatory pressures to incorporate diversity, equity, and inclusion (DE&I), and suffered the impacts of geopolitical conflicts. Last year, we concluded with a cautiously optimistic outlook, anticipating the industry’s imminent breakthrough in clinical trial innovation.
Continuing with our annual tradition of Clinical Trials Roundup review, the 2024 analysis focuses on an overview of the Phase I–III clinical trials that initiated in the prior calendar year (2023) across all therapeutic areas (TAs) comprehensively covered by Trialtrove, as well as in-depth analyses into the key diseases, sponsoring companies, and geographies that impact the pharmaceutical industry. We will survey the recovery in clinical trial activity that occurred as the pandemic gradually deescalated to an endemic and how it reflects the current clinical landscape.
Read more..
About the author
Heidi Chen
Associate Director, Research & Commercial Services, Citeline
Heidi Chen supports client engagement with Citeline content through a deep understanding of customer business needs, seasoned expertise in proprietary platforms, market analysis, and commercial activities. She oversees Citeline's production of customized Platinum Datapacks across hot topic facing industry today.
Heidi draws from her pharmaceutical industry experience as a drug discover scientist and over two decades of therapy-area expertise in CNS, immunology, and ophthalmology. Within this remit, she collaborates across various functional groups within Citeline, and contributes towards projects such as consulting engagements, webinars, and thought leadership white papers.
